NewsBenzinga아큐티스 바이오테라퓨틱스, ACAAI 연례 학술회의에서 조리브 크림 0.05%를 지지하는 INTEGUMENT-INFANT 임상시험의 새로운 보호자 보고 결과 데이터 발표 아큐티스 바이오테라퓨틱스, ACAAI 연례 학술회의에서 조리브 크림 0.05%를 지지하는 INTEGUMENT-INFANT 임상시험의 새로운 보호자 보고 결과 데이터 발표 Benzinga 2026.11.13 14:03 (GMT+0) Open on Benzinga Other news 'China Taps US AI Models To Train Homegrown Rivals As Chip Curbs Bite' - Reuters Exclusive 'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century' A-Share Close: ChiNext Index Down Over 1% After Intraday Reversal, More Than 4,100 Stocks Fall Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY
'Ruined The System'? Pete Buttigieg Pushes Back On Trump's FAA Blame, Demands Accounting for Billions In Modernization Funds After 'Worst FAA Communications Breakdown This Century'
Reported Earlier, Lecanemab Five-Year Clarity AD Data: 36% Lower Relative Risk Of Disease-Stage Progression Vs. ADNI, 62% Of Low-Tau Patients Improved On CDR-SB, Consistent Safety Profile, Per Eisai And Biogen
Reported Earlier, MediaCo Holding Q3 EPS $(0.11) Up From $(0.22) YoY, Sales $28.600M Down From $35.398M YoY